P-099 Sex-Based Differences in Adverse Events of Crohnʼs Disease Patients Treated with Certolizumab Pegol
نویسندگان
چکیده
منابع مشابه
Certolizumab pegol in the treatment of Crohn's disease.
INTRODUCTION The introduction of antibodies directed against tumour necrosis factor (anti-TNF) has dramatically changed the concept of treating patients with Crohn's disease (CD). Unfortunately, the long-term efficacy of anti-TNF agents may be hampered by immunogenicity. The availability of more anti-TNF agents in the therapeutic armamentarium would therefore be of great benefit in patients loo...
متن کاملExposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
BACKGROUND Therapeutic drug monitoring may optimize therapy for Crohn's disease (CD). AIM To use a population pharmacokinetic model that accounts for the time-varying nature of covariates to simulate certolizumab pegol (CZP) concentrations to evaluate the exposure-response relationship for CZP in Crohn's disease. METHODS Adults (N = 2157) with Crohn's disease were treated with CZP in nine c...
متن کاملCertolizumab pegol for the treatment of Crohn's disease.
In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn's disease (CD). The results from a comprehensive clinical trial program suggest that certolizumab pegol offers rapid and sustained remission of moderate ...
متن کاملCertolizumab pegol: an evidence-based review of its place in the treatment of Crohn’s disease
INTRODUCTION Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by a relapsing/remitting course with transmural inflammation of potentially any section of the digestive tract. Certolizumab pegol (CZP) is a pegylated Fc-free Fab' fragment of a humanized anti-TNF-alfa monoclonal antibody that is in development for clinical use in CD. AIMS To review the available data wit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Inflammatory Bowel Diseases
سال: 2016
ISSN: 1078-0998
DOI: 10.1097/01.mib.0000480204.52524.a5